Literature DB >> 11334557

Characterization of the prostaglandin receptors in human osteoblasts in culture.

P Sarrazin1, G Bkaily, R Haché, C Patry, R Dumais, F A Rocha, A J de Brum-Fernandes.   

Abstract

Prostaglandins have complex actions on bone metabolism that depend on interactions with different types and subtypes of receptors. Our objective was to characterize the prostaglandins receptors present in primary cultures of human osteoblasts. RT-PCR analysis revealed the presence of DP, EP(4), IP, FP and TP receptor mRNA in primary cultures of human osteoblasts. FP receptor mRNA was detected only after 3 weeks of confluency, all the others were detected at every culture time tested. To verify the functionality of these receptors we challenged the cells with the prostanoids and synthetic analogues and determined the intracellular levels of cAMP. All receptors found by RT-PCR were coupled to second messengers except for the DP subtype. These results clearly show the presence of functional EP(4), IP, FP and TP receptors in human osteoblasts in culture. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334557     DOI: 10.1054/plef.1999.0127

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

1.  Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors.

Authors:  Steeve Kwan Tat; Jean-Pierre Pelletier; Daniel Lajeunesse; Hassan Fahmi; Nicolas Duval; Johanne Martel-Pelletier
Journal:  Bone       Date:  2008-04-26       Impact factor: 4.398

2.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

3.  Prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells.

Authors:  Oliver Kemper; Monika Herten; Johannes Fischer; Marcel Haversath; Sascha Beck; Tim Classen; Sebastian Warwas; Tjark Tassemeier; Stefan Landgraeber; Sabine Lensing-Höhn; Rüdiger Krauspe; Marcus Jäger
Journal:  Med Sci Monit       Date:  2014-11-10

4.  Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.

Authors:  Gianfranco Caselli; Albino Bonazzi; Marco Lanza; Flora Ferrari; Daniele Maggioni; Cristian Ferioli; Roberto Giambelli; Eleonora Comi; Silvia Zerbi; Marco Perrella; Ornella Letari; Elena Di Luccio; Milena Colovic; Stefano Persiani; Tiziano Zanelli; Laura Mennuni; Tiziana Piepoli; Lucio Claudio Rovati
Journal:  Arthritis Res Ther       Date:  2018-03-01       Impact factor: 5.156

5.  Expression of Prostaglandin E2 Receptors in Acquired Middle Ear Cholesteatoma.

Authors:  Sujie Wang; Li Xie; Yanfei Zhang; Pengfei Xu; Aiguo Liu
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-08-26       Impact factor: 3.372

6.  In Vivo Bone Effects of a Novel Bisphosphonate-EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model.

Authors:  Zeeshan Sheikh; Gang Chen; Faik Al-Jaf; Marion Thévenin; Kate Banks; Michael Glogauer; Robert N Young; Marc D Grynpas
Journal:  JBMR Plus       Date:  2019-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.